Background: UNVEIL is the first study of apremilast in patients (pts) with moderate psoriasis
(body surface area [BSA] 5%-10%) naive to biologic and systemic therapy. Physician and pt …

Abstract Introduction and Objectives: Patients (pts) with moderate plaque psoriasis are often
inadequately treated (Armstrong, 2013), and there remains an unmet medical need for an …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Background Pharmacodynamic (PD) subanalyses of clinical trials in patients with moderate
to severe psoriasis demonstrated the efficacy of apremilast correlated with reductions in …

OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral
PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …

Background Despite the proven efficacy and safety of apremilast to treat plaque psoriasis
(PsO), data regarding its real‐world use and patient‐perceived benefits are limited …

Background: In ADVANCE (NCT03721172), apremilast 30 mg BID (APR) demonstrated
significantly greater sPGA response vs. PBO at Week 16 (22% vs. 4%; P<. 0001) in patients …